The Center on Alcohol, Substance use, And Addictions (CASAA) investigator Frank Schwebel, Ph.D., is partnering with a mobile company for a brand-new study.
The Mindfulness and Medication Adherence (MiMA) Study is a digital intervention designed to support people taking medications for opioid use disorder and chronic pain. This project uses digital health to deliver a behavioral health intervention grounded in Mindfulness-Based Relapse Prevention (MBRP) and Acceptance and Commitment Therapy (ACT).
Schwebel said the goals are to improve treatment outcomes by delivering a tailored digital health intervention that increases medication adherence rates, reduces cravings and withdrawal symptoms, and helps individuals manage chronic pain.
The project is collecting real-time data through ecological momentary assessment (EMA) to better understand how this digital intervention impacts participant behaviors and health.
"We're leveraging innovative, evidence-based digital tools to extend behavioral health support beyond traditional care environments," Schwebel said. "This is particularly important for people struggling with access to care or facing long-term episodes of care like people with chronic pain and opioid use disorder."
The project is funded by the National Institute on Drug Abuse and the intervention was built in collaboration with Schwebel at CASAA and MEMOTEXT, a digital health company specializing in personalized communication for behavior change.
